CORDIS
EU research results

CORDIS

English EN
Development & Evaluation of a Viable Stent Device for the Treatment of BronchoTracheal Cancer

Development & Evaluation of a Viable Stent Device for the Treatment of BronchoTracheal Cancer

Objective

Lung cancer is the most common cancer in terms of both incidence and mortality, worldwide. With a median age at diagnosis of 71, lung cancer is mainly affecting the aging population. Airway stenosis is a key problem with significant morbidity and premature death. Endobronchial stenting is a proven therapy to keep the airways open. Nevertheless the currently used clinical stents have major disadvantages either by rapid re-occlusion due to tumour ingrowths (metal stents) or massive mucus retention due to the interrupted mucociliary function (coated stents).
The aim of the project is to develop a viable endobronchial stent (syn. PulmoStent) for the treatment of broncho-tracheal cancer diseases. The concept is based on the combination of stent technologies with the principles of tissue engineering. The PulmoStent is a multi-layered structure providing (1) a functional respiratory epithelium on the luminal side, which allows the maintenance of the mucociliary function in the stented area, (2) an embedded micro- or nanosphere formulations, enabling the sustained, local release of tumour-specific therapeutics in combination with (3) a mechanical separating layer on the external side, enabling a local tumour suppression to avoid stent displacement and restenosis by a growing tumour.
The PulmoStent is a step change beyond the state-of-the-art from a passive to a viable and functional active implant tailored to the patient. It focuses on a clearly identified clinical need for the treatment of lung cancer. The combination of different kinds of biomaterials to a co-scaffold system for the bio-functionalization of the stent will lead to an improved performance of endobronchial stents and thereby to longer durability. The novel PulmoStent will improve the quality of life and increase the life expectancy of lung cancer patients, because of the reduced mucus retention in the stented area, and herewith the reduced risk of life-threatening pneumonia and the local tumour suppression.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAETSKLINIKUM AACHEN

Address

Pauwelsstrasse 30
52074 Aachen

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 710 902,92

Administrative Contact

Volker Legewie

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

NATIONAL UNIVERSITY OF IRELAND GALWAY

Ireland

EU Contribution

€ 557 980

RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN

Germany

EU Contribution

€ 383 074

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 406 863

EPITHELIX SARL

Switzerland

EU Contribution

€ 419 610

ITA TECHNOLOGIETRANSFER GMBH

Germany

EU Contribution

€ 184 016

VYSERA BIOMEDICAL LIMITED

Ireland

EU Contribution

€ 367 847

NONWOTECC MEDICAL GMBH

Germany

EU Contribution

€ 137 406,08

Project information

Grant agreement ID: 280915

Status

Closed project

  • Start date

    1 April 2012

  • End date

    31 March 2015

Funded under:

FP7-NMP

  • Overall budget:

    € 4 085 248,53

  • EU contribution

    € 3 167 699

Coordinated by:

UNIVERSITAETSKLINIKUM AACHEN

Germany